Multispecific binding proteins with mutant fab domains

Patent metadata

Field	Value
Publication number	US-11965030-B2
Application number	US-201916725228-A
Country	US
Kind code	B2
Filing date	Dec 23, 2019
Priority date	Dec 24, 2018
Publication date	Apr 23, 2024
Grant date	Apr 23, 2024

Abstract

Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

First claim

What is claimed is:

1. A multispecific antigen-binding protein comprising at least two VL regions respectively paired with at least two VH regions to form at least two antigen-binding sites and at least two CH1 regions respectively paired with two CL regions,
wherein at least one CH1/CL pair comprises a CH1 region comprising K221E and K228D mutations at Kabat positions 221 and 228 and CL region comprising D122K and E123K mutations at Kabat positions 122 and 123 to facilitate pairing, and
wherein at least one VH/VL pair comprises opposite charged mutations to facilitate pairing, said opposite charged mutations comprising (1) a mutated residue in the VH region at Kabat position 39 selected from E, D, K, R, or H, and (2) a mutated residue in the VL region at Kabat position 38 selected from E, D, K, R, or H, and
wherein the mutated residue in the VH region has an opposite charge from the mutated residue in the VL region.

2. A multispecific antigen-binding protein comprising:
a) a first light chain (LC1)/heavy chain (HC1) pair comprising:
(1) a first VL region (VL1) paired with first VH region (VH1) to form a first antigen-binding site;
(2) a first constant heavy chain region 1 (CH1-1) operatively linked to VH1 and a first constant light chain region (CL1) operatively linked to VL1; and
(3) a first heterodimerization domain (HD1); and

b) a second light chain (LC2)/heavy chain (HC2) pair comprising:
(4) a second VL region (VL2) paired with a second VH region (VH2) to form a second antigen-binding site;
(5) a second constant heavy chain region 1 (CH1-2) operatively linked to VH2 and a second constant light chain region (CL2) operatively linked to VL2; and
(6) a second heterodimerization domain (HD2);
wherein HD1 and HD2 heterodimerize,
wherein at least one or both of VL1 and VH1 pair and of VL2 and VH2 pair comprises opposite charged mutations to facilitate pairing, said opposite charged mutations comprising (1) a mutated residue in the VH region at Kabat position 39 selected from E, D, K, R, or H, and (2) a mutated residue in the VL region at Kabat position 38 selected from E, D, K, R, or H, and wherein the mutated residue in the VH region has an opposite charge from the mutated residue in the VL region,
wherein at least one or both of CL1 and CH1-1 pair and of CL2 and CH1-2 pair comprises mutations to facilitate pairing, and
wherein when both of CL1 and CH1-1 pair and of CL2 and CH1-2 pair comprise mutations to facilitate pairing, the mutations in CH1-1 and CL1 to facilitate pairing are different from the mutations in CH1-2 and CL2 to facilitate pairing, wherein:
i) CH1-1 comprises a T192E mutation and CL1 comprises N137K and S114A mutations and/or CH1-2 comprises a T192E mutation and CL2 comprises N137K and S114A mutations;
ii) CH1-1 comprises L143Q and S188V mutations and CL1 comprises V133T and S176V mutations and/or CH1-2 comprises L143Q and S188V mutations and CL2 comprises V133T and S176V mutations;
iii) CH1-1 comprises T192E, L143Q and S188V mutations and CL1 comprises N137K, S114A, V133T and S176V mutations and/or CH1-2 comprises T192E, L143Q and S188V mutations and CL2 comprises N137K, S114A, V133T and S176V mutations;
iv) CH1-1 comprises a K221E mutation and CL1 comprises a E123K mutation and/or CH1-2 comprises a K221E mutation and CL2 comprises a E123K mutation;
v) CH1-1 comprises T192E and K221E mutations and CL1 comprises N137K, S114A and E123K mutations and/or CH1-2 comprises T192E and K221E mutations and CL2 comprises N137K, S114A and E123K mutations;
vi) CH1-1 comprises a K228D mutation and CL1 comprises a D122K mutation and/or CH1-2 comprises a K228D mutation and CL2 comprises a D122K mutation;
vii) CH1-1 comprises K221E and K228D mutations and CL1 comprises D122K and E123K mutations and/or CH1-2 comprises K221E and K228D mutations and CL2 comprises D122K and E123K mutations;
viii) CH1-1 comprises a L143E, a L143D, a L143K, a L143R, or a L143H mutation, and CL1 comprises a S176E, a S176D, a S176K, a S176R, or a S176H mutation and/or CH1-2 comprises a L143E, a L143D, a L143K, a L143R, or a L143H mutation, and CL2 comprises a S176E, a S176D, a S176K, a S176R, or a S176H mutation; and/or
ix) CH1-1 comprises a L124E, a L124D, a L124K, a L124R, or a L124H mutation, and CL1 comprises a V133E, a V133D, a V133K, a V133R, or a V133H mutation and/or CH1-2 comprises a L124E, a L124D, a L124K, a L124R, or a L124H mutation, and CL2 comprises a V133E, a V133D, a V133K, a V133R, or a V133H mutation,
wherein the mutations are according to Kabat numbering.

3. The multispecific antigen-binding protein of claim 1 , wherein at least one CH1 region is operably linked to a heterodimerization domain.

4. A multispecific antigen-binding protein comprising four polypeptide chains, that form three antigen-binding sites, wherein
a first polypeptide chain comprises a structure represented by the formula:
VL2-L1-VL1-L2-CL1  [I],

a second polypeptide chain comprises a structure represented by the formula:
VH1-L3-VH2-L4-CH1-1-hinge-CH2-CH3  [II],

a third polypeptide chain comprises a structure represented by the formula:
VH3-CH1-2-hinge-CH2-CH3  [III], and

a fourth polypeptide chain comprises a structure represented by the formula:
VL3-CL2  [IV],

wherein:
VL1 is a first immunoglobulin light chain variable domain;
VL2 is a second immunoglobulin light chain variable domain;
VL3 is a third immunoglobulin light chain variable domain;
VH1 is a first immunoglobulin heavy chain variable domain;
VH2 is a second immunoglobulin heavy chain variable domain;
VH3 is a third immunoglobulin heavy chain variable domain;
CL1 is a first immunoglobulin light chain constant domain;
CL2 is a second immunoglobulin light chain constant domain;
CH1-1 is a first immunoglobulin CH1 heavy chain constant domain;
CH1-2 is a second immunoglobulin CH1 heavy chain constant domain;
CH2 is an immunoglobulin CH2 heavy chain constant domain;
CH3 is an immunoglobulin CH3 heavy chain constant domain;
hinge is an immunoglobulin hinge region connecting the CH1 and CH2 domains;
Fc comprises an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains; and
L1, L2, L3, and L4 are amino acid linkers,
wherein VH1 is paired with VL1, VH2 is paired with VL2, and CH1-1 is paired with CL1,
wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair,
wherein one or more cysteine residues are engineered into the one or more of VH1/VL1, VH2/VL2, and VH3/VL3 pairs to form one or more disulfide bonds,
wherein at least one or both of VL1 and VH1 pair and of VL2 and VH2 pair comprises opposite charged mutations that facilitate pairing, said opposite charged mutations comprising (1) a mutated residue in the VH region at Kabat position 39 selected from E, D, K, R, or H, and (2) a mutated residue in the VL region at Kabat position 38 selected from E, D, K, R, or H,
wherein the mutated residue in the VH region has an opposite charge from the mutated residue in the VL region, and
wherein one or both of the CH1-1 and CL1 domain pair and the CL2 and CH1-2 domain pair comprise mutations that facilitate pairing,
wherein when both of CL1 and CH1-1 pair and of CL2 and CH1-2 pair comprise mutations to facilitate pairing, the mutations in CH1-1 and CL1 are different than the mutations in CH1-2 and CL2, wherein:
i) CH1-1 comprises a T192E mutation and CL1 comprises N137K and S114A mutations and/or CH1-2 comprises a T192E mutation and CL2 comprises N137K and S114A mutations:

ii) CH1-1 comprises L143Q and S188V mutations and CL1 comprises V133T and S176V mutations and/or CH1-2 comprises L143Q and S188V mutations and CL2 comprises V133T and S176V mutations;
iii) CH1-1 comprises T192E, L143Q and S188V mutations and CL1 comprises N137K, S114A, V1

Assignees

• Sanofi Sa

Inventors

• Amaral Marta
• Beil Christian
• Focken Ingo
• Hessler Gerhard
• Hoelper Soraya
• Jung Jennifer
• Lange Christian
• Leuschner Wulf-Dirk
• Rao Ercole
• Tiwari Garima
• Weil Sandra

Classifications

• C07K16/2878 Primary

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/522

  CH1 domain · CPC title

• C07K2317/524

  CH2 domain · CPC title